Coya Therapeutics, a clinical-stage biotechnology firm specializing in biologics to enhance regulatory T cell (Treg) function, will present data from its phase 2, double-blind, placebo-controlled study of interleukin-2 (IL-2) for mild to moderate Alzheimer’s Disease at the 17th Clinical Trials…
Today, a groundbreaking environmental health impact initiative was announced to assist those most vulnerable to extreme weather events, which can exacerbate existing chronic conditions. Initially, the initiative will focus on extreme heat events by providing timely excessive heat alerts and…
AbbVie today announced the completion of its acquisition of Cerevel Therapeutics (NASDAQ: CERE), making Cerevel a part of AbbVie. “AbbVie’s acquisition of Cerevel strengthens our foundation in neuroscience and positions us for sustainable long-term performance into the next decade and…
BioNTech Announces Promising Phase 2 Results for mRNA Immunotherapy BNT111 in Advanced Melanoma BioNTech today revealed positive topline data from its ongoing Phase 2 clinical trial (EudraCT No.: 2020-002195-12; NCT04526899) involving patients with unresectable stage III or IV melanoma whose…
The interim analysis of the AMPLIFY Phase III trial revealed promising results for AstraZeneca’s Calquence (acalabrutinib) combined with venetoclax, with or without obinutuzumab, in treating chronic lymphocytic leukaemia (CLL). The study showed a significant improvement in progression-free survival (PFS) compared…
Allergan Aesthetics is excited to announce the return of JUVÉDERM® Day on Wednesday, August 21. Following the success of its inaugural event, JUVÉDERM® Day offers limited-time deals, savings, and exclusive promotions through Allē, Allergan Aesthetics’ loyalty rewards program. “JUVÉDERM® Day…
MSD, known as Merck outside the United States and Canada, has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of KEYTRUDA, Merck’s anti-PD-1 therapy. This recommendation…
Autobahn Therapeutics, a biotech firm focused on innovative treatments for neuropsychiatric and neuroimmunologic disorders, has closed an oversubscribed $100 million Series C financing round. The funding was led by Newpath Partners and included new investors Canaan Partners, Monograph Capital, and…
PK MED, a French biotech company established in 2019 by Truffle Capital, has secured €1.5 million in non-dilutive DeepTech financing from Bpifrance. This funding will drive the development of PKM-02, a cutting-edge cell-homing technology designed to improve bone marrow transplantation…
Nuvation Bio, a late-stage global biopharmaceutical company focused on oncology, has announced several updates for its taletrectinib program. Data from the global, pivotal Phase 2 TRUST-II study will be presented orally at the World Conference on Lung Cancer (WCLC) 2024,…
Hims & Hers Health, a leading health and wellness platform, has announced the appointment of Kåre Schultz to its Board of Directors. Schultz, known for his extensive global expertise in healthcare and pharmaceuticals, brings decades of experience from his roles…
Gilead Sciences, Inc. (Nasdaq: GILD) and the Elton John AIDS Foundation (EJAF) have announced a five-year extension of the RADIAN® partnership to address the growing HIV crisis in Eastern Europe and Central Asia (EECA). This partnership aims to support vulnerable…
